A pharmaceutical company is developing a new anticancer drug that binds to the allosteric site of ribonucleotide reductase, reducing its activity without competing with the substrate (deoxyribonucleotide triphosphates). To confirm the non-competitive nature of this inhibition and rule out mixed-type inhibition, which investigation would be most appropriate?